221 results on '"Catarina Xavier"'
Search Results
152. Effect of charges of radiolabeled Nanobodies on kidney retention
153. Nanobody-based PET/CT imaging of HER2 expression in breast carcinoma: Phase I results and potential to assess tumor heterogeneity
154. Design and Preclinical Evaluation Of A Single-Label Bimodal Nanobody Tracer for Image-Guided Surgery
155. Validation of biodistribution, tumor targeting and dosimetry of 68Ga-NOTA-Anti-MMR Nanobody for PET imaging of the inflammatory tumor microenvironment
156. 18F-Anti-VCAM-1 Nanobody for PET/CT Imaging of Inflamed Atherosclerotic Plaques
157. Nanobodies: Versatile diagnostic tools and next-generation probes for imaging and molecular therapies
158. Image-guided surgery of intraperitoneally disseminated tumor lesions using near-infrared fluorescently-labeled nanobodies
159. Immuno-imaging using nanobodies
160. Sortase as a tool to produce nanobody-based radiopharmaceuticals for theranostics
161. Synthesis, characterization, and evaluation of a novel (99)mTc(CO)(3) pyrazolyl conjugate of a peptide nucleic acid sequence
162. Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody
163. Sortase as a tool to produce nanobody based radiopharmaceuticals for theranostics
164. 18F-Anti-MMR-Nanobodies for immunoPET imaging of tumour-associated macrophages in the tumour microenvironment
165. Astatinated nanobodies, a promising new approach in targeted alpha therapy. A preclinical study
166. A comparison of [68Ga]Ga-NOTA-anti-HER2-sdAb PET/CT with [18F]FDG-PET/CT in breast carcinoma patients
167. Site-specific Radiolabeling Strategies For PET Imaging: Development Of Human PD-L1 Nanobody
168. Evaluating a human PD-L1 (huPD-L1) specific single domain antibody (sdAb) as a theranostic
169. Synthesis, preclinical validation, dosimetry and toxicity of 68Ga-NOTA-Anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer
170. Effect of charges on the kidney retention of site-specific labelled Nanobodies
171. Radiometal labeling of anti-VCAM-1 nanobody for imaging of atherosclerosis - Impact of radiochemistry on pharmacokinetics
172. Effect of Nanobody-based radiopharmaceuticals on kidney retention
173. Targeted radionuclide therapy of Non-Hodgkin lymphoma with 177Lu-radiolabeled anti-hCD20 sdAb
174. In vivo optical imaging with NIR-nanobodies - Optimization of the fluorescent dye for improved pharmacokinetics
175. Ga-68 anti-HER2 nanobodies labeled via NOTA for immuno-PET of breast cancer
176. Melanoma targeting with alpha-melanocyte stimulating hormone analogs labeled with fac-(Tc-99m(CO)(3))(+): Effect of cyclization on tumor-seeking properties
177. Site-specific radiolabelling strategies of the anti-human PD-L1 Nanobody for PET imaging
178. Site-Specific Radiolabeling of a Human PD-L1 Nanobody via Maleimide–Cysteine Chemistry
179. A site-specific radiolabelling strategy of Nanobodies for PET imaging
180. Precinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer
181. Nanobody-based targeted radionuclide therapy for cancer treatment
182. Anti-CD20 nanobody based targeted radionuclide therapy of Non-Hodgkin Lymphoma
183. Evaluating a single domain antibody specific for human PD-L1 as a cancer nuclear imaging and therapy agent
184. Molecular imaging of inflamed atherosclerotic plaque using 18F-anti-VCAM-1 nanobody and PET/CT
185. Nanoplatforms for Bimodal Imaging of Sentinel Lymph Node
186. Human PD-L1 Nanobody for PET imaging: a site-specific radiolabelling strategy
187. Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent
188. Theranostic radiolabeled anti-CD20 nanobody for targeted radionuclide therapy of Non-Hodgkin Lymphoma
189. Tricarbonyl M(I) (M = Re, (99m)Tc) complexes bearing acridine fluorophores: synthesis, characterization, DNA interaction studies and nuclear targeting
190. Site-specific labeling of cysteine-tagged camelid single-domain antibody-fragments for use in molecular imaging
191. Development of (177) Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer: evaluation of different bifunctional chelators
192. Bimodal imaging of sentinel lymph node with 99mTc(CO)3-labeled mannosylated nanoparticles bearing a NIR-fluorophore
193. Synthesis, preclinical validation and toxicology of 68Ga-NOTA-Anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer
194. Site-specifically radiolabelled Human PD-L1 Nanobody: a new tool for clinical PET imaging
195. Molecular imaging of inflammed atherosclerotic plaque using 18F-Anti-VCAM-1 Nanobody and PET/CT
196. Human PD-L1 Nanobody For Immuno-PET Imaging: Sites-pecific Radiolabeling Strategies
197. 131I-labeled anti-HER2 nanobody as a theranostic tool in cancer treatment
198. Evaluating a human PD-L1 specific single domain antibody as a theranostic
199. Improved detection of molecular markers of atherosclerotic plaques using sub-millimetre PET imaging
200. Development and inter-laboratory validation of the VISAGE enhanced tool for age estimation from semen using quantitative DNA methylation analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.